;PMID: 10197610
;source_file_1215.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:40..159] = [t:40..159]
;2)section:[e:163..231] = [t:163..231]
;3)section:[e:235..330] = [t:235..330]
;4)sentence:[e:334..636] = [t:334..636]
;5)sentence:[e:637..744] = [t:637..744]
;6)sentence:[e:745..898] = [t:745..898]
;7)sentence:[e:899..1059] = [t:899..1059]
;8)sentence:[e:1060..1255] = [t:1060..1255]
;9)sentence:[e:1256..1371] = [t:1256..1371]
;10)sentence:[e:1372..1616] = [t:1372..1616]
;11)sentence:[e:1617..1806] = [t:1617..1806]
;12)section:[e:1810..1855] = [t:1810..1855]

;section 0 Span:0..35
;Cancer Res  1999 Apr 1;59(7):1442-4
(SEC
  (FRAG (NN:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 1999) (.:[17..20] Apr)
        (CD:[21..26] 1;59-LRB-) (CD:[26..28] 7-RRB-) (CD:[28..33] :1442)
        (::[33..34] -) (CD:[34..35] 4)))

;sentence 1 Span:40..159
;Beta-catenin mutations are more frequent in small colorectal adenomas than in
; larger adenomas and invasive carcinomas.
;[40..52]:gene-rna:"Beta-catenin"
;[84..109]:malignancy:"small colorectal adenomas"
;[119..134]:malignancy:"larger adenomas"
;[139..158]:malignancy:"invasive carcinomas"
(SENT
  (S
    (NP-SBJ (NN:[40..52] Beta-catenin) (NNS:[53..62] mutations))
    (VP (VBP:[63..66] are)
      (ADJP-PRD
        (ADJP (RBR:[67..71] more) (JJ:[72..80] frequent))
        (PP-1 (-NONE-:[80..80] *ICH*)))
      (PP-LOC (IN:[81..83] in)
        (NP (JJ:[84..89] small) (JJ:[90..100] colorectal)
            (NNS:[101..109] adenomas)))
      (PP-1 (IN:[110..114] than)
        (PP (IN:[115..117] in)
          (NP
            (NP (JJR:[119..125] larger) (NNS:[126..134] adenomas))
            (CC:[135..138] and)
            (NP (JJ:[139..147] invasive) (NNS:[148..158] carcinomas))))))
    (.:[158..159] .)))

;section 2 Span:163..231
;Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F, Slattery ML.
(SEC
  (FRAG (NNP:[163..171] Samowitz) (NNP:[172..174] WS) (,:[174..175] ,)
        (NNP:[176..182] Powers) (NNP:[183..185] MD) (,:[185..186] ,)
        (NNP:[187..193] Spirio) (NNP:[194..196] LN) (,:[196..197] ,)
        (NNP:[198..204] Nollet) (NNP:[205..206] F) (,:[206..207] ,)
        (NNP:[208..211] van) (NNP:[212..215] Roy) (NNP:[216..217] F)
        (,:[217..218] ,) (NNP:[219..227] Slattery) (NNP:[228..231] ML.)))

;section 3 Span:235..330
;Department of Pathology, University of Utah Health Sciences Center, Salt Lake
; City 84132, USA.
(SEC
  (FRAG (NNP:[235..245] Department) (IN:[246..248] of)
        (NNP:[249..258] Pathology) (,:[258..259] ,) (NNP:[260..270] University)
        (IN:[271..273] of) (NNP:[274..278] Utah) (NNP:[279..285] Health)
        (NNP:[286..294] Sciences) (NNP:[295..301] Center) (,:[301..302] ,)
        (NNP:[303..307] Salt) (NNP:[308..312] Lake) (NNP:[314..318] City)
        (POS:[319..324] 84132) (NNPS:[324..325] ,) (NNP:[326..329] USA)
        (.:[329..330] .)))

;sentence 4 Span:334..636
;Loss of serine or threonine phosphorylation sites from exon 3 of beta-catenin
; has been identified in approximately half of colorectal tumors which lack 
;adenomatous polyposis coli (APC) mutations, but the overall contribution of 
;beta-catenin mutations to sporadic colorectal tumorigenesis is unclear.
;[389..395]:variation-location:"exon 3"
;[399..411]:gene-rna:"beta-catenin"
;[458..475]:malignancy:"colorectal tumors"
;[488..514]:gene-rna:"adenomatous polyposis coli"
;[516..519]:gene-rna:"APC"
;[565..577]:gene-rna:"beta-catenin"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (NN:[334..338] Loss))
        (PP (IN:[339..341] of)
          (NP
            (NP
              (NP (NN:[342..348] serine)
                (NML-1 (-NONE-:[348..348] *P*)))
              (CC:[349..351] or)
              (NP (NN:[352..361] threonine)
                (NML-1 (NN:[362..377] phosphorylation) (NNS:[378..383] sites))))
            (PP (IN:[384..388] from)
              (NP
                (NP (NN:[389..393] exon) (CD:[394..395] 3))
                (PP (IN:[396..398] of)
                  (NP (NN:[399..411] beta-catenin))))))))
      (VP (VBZ:[413..416] has)
        (VP (VBN:[417..421] been)
          (VP (VBN:[422..432] identified)
            (NP-2 (-NONE-:[432..432] *))
            (PP-LOC (IN:[433..435] in)
              (NP
                (NP
                  (QP (RB:[436..449] approximately) (NN:[450..454] half)))
                (PP (IN:[455..457] of)
                  (NP
                    (NP (JJ:[458..468] colorectal) (NNS:[469..475] tumors))
                    (SBAR
                      (WHNP-3 (WDT:[476..481] which))
                      (S
                        (NP-SBJ-3 (-NONE-:[481..481] *T*))
                        (VP (VBP:[482..486] lack)
                          (NP
                            (NML
                              (NML (JJ:[488..499] adenomatous)
                                   (NN:[500..509] polyposis)
                                   (NN:[510..514] coli))
                              (NML (-LRB-:[515..516] -LRB-) (NN:[516..519] APC)
                                   (-RRB-:[519..520] -RRB-)))
                            (NNS:[521..530] mutations)))))))))))))
    (,:[530..531] ,) (CC:[532..535] but)
    (S
      (NP-SBJ
        (NP (DT:[536..539] the) (JJ:[540..547] overall)
            (NN:[548..560] contribution))
        (PP (IN:[561..563] of)
          (NP (NN:[565..577] beta-catenin) (NNS:[578..587] mutations)))
        (PP (TO:[588..590] to)
          (NP (JJ:[591..599] sporadic) (JJ:[600..610] colorectal)
              (NN:[611..624] tumorigenesis))))
      (VP (VBZ:[625..627] is)
        (ADJP-PRD (JJ:[628..635] unclear))))
    (.:[635..636] .)))

;sentence 5 Span:637..744
;We  therefore used PCR to amplify and sequence exon 3 of beta-catenin from
;202  sporadic colorectal tumors.
;[684..690]:variation-location:"exon 3"
;[694..706]:gene-rna:"beta-catenin"
;[717..743]:malignancy:"sporadic colorectal tumors"
(SENT
  (S
    (NP-SBJ (PRP:[637..639] We))
    (ADVP (RB:[641..650] therefore))
    (VP (VBD:[651..655] used)
      (NP (NN:[656..659] PCR))
      (S-MNR
        (NP-SBJ (-NONE-:[659..659] *))
        (VP (TO:[660..662] to)
          (VP (VB:[663..670] amplify) (CC:[671..674] and)
              (VB:[675..683] sequence)
            (NP
              (NP (NN:[684..688] exon) (CD:[689..690] 3))
              (PP (IN:[691..693] of)
                (NP (NN:[694..706] beta-catenin)))
              (PP (IN:[707..711] from)
                (NP (CD:[712..715] 202)
                   (JJ:[717..725] sporadic) (JJ:[726..736] colorectal)
                   (NNS:[737..743] tumors))))))))
    (.:[743..744] .)))

;sentence 6 Span:745..898
;Exon 3 beta-catenin mutations were identified in 6  of 48 small (< 1 cm)
;adenomas, 2 of 82 large (> or =1 cm) adenomas, and 1 of 72  invasive
;carcinomas.
;[745..751]:variation-location:"Exon 3"
;[752..764]:gene-rna:"beta-catenin"
;[803..808]...[818..826]:malignancy:"small"..."adenomas"
;[836..841]...[855..863]:malignancy:"large"..."adenomas"
;[878..897]:malignancy:"invasive carcinomas"
(SENT
  (S
    (NP-SBJ-1
      (NML (NN:[745..749] Exon) (CD:[750..751] 3))
      (NN:[752..764] beta-catenin) (NNS:[765..774] mutations))
    (VP (VBD:[775..779] were)
      (VP (VBN:[780..790] identified)
        (NP-1 (-NONE-:[790..790] *))
        (PP-LOC (IN:[791..793] in)
          (NP
            (NP
              (NP (CD:[794..795] 6))
              (PP (IN:[797..799] of)
                (NP (CD:[800..802] 48) (JJ:[803..808] small)
                  (PRN (-LRB-:[809..810] -LRB-)
                    (NP
                      (QP (SYM:[810..811] <) (CD:[812..813] 1))
                      (NN:[814..816] cm))
                    (-RRB-:[816..817] -RRB-))
                  (NNS:[818..826] adenomas))))
            (,:[826..827] ,)
            (NP
              (NP (CD:[828..829] 2))
              (PP (IN:[830..832] of)
                (NP (CD:[833..835] 82) (JJ:[836..841] large)
                  (PRN (-LRB-:[842..843] -LRB-)
                    (NP
                      (QP (SYM:[843..844] >) (CC:[845..847] or)
                          (SYM:[848..849] =) (CD:[849..850] 1))
                      (NN:[851..853] cm))
                    (-RRB-:[853..854] -RRB-))
                  (NNS:[855..863] adenomas))))
            (,:[863..864] ,) (CC:[865..868] and)
            (NP
              (NP (CD:[869..870] 1))
              (PP (IN:[871..873] of)
                (NP (CD:[874..876] 72)
                   (JJ:[878..886] invasive) (NNS:[887..897] carcinomas))))))))
    (.:[897..898] .)))

;sentence 7 Span:899..1059
;Eight of the nine mutations, including all of those in the  small adenomas
;and the invasive cancer, involved loss of serine or threonine 
;phosphorylation sites.
;[917..926]:variation-event:"mutations"
;[959..973]:malignancy:"small adenomas"
;[982..997]:malignancy:"invasive cancer"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[899..904] Eight))
      (PP (IN:[905..907] of)
        (NP (DT:[908..911] the) (CD:[912..916] nine) (NNS:[917..926] mutations)))
      (,:[926..927] ,)
      (PP (VBG:[928..937] including)
        (NP
          (NP (DT:[938..941] all))
          (PP (IN:[942..944] of)
            (NP
              (NP (DT:[945..950] those))
              (PP (IN:[951..953] in)
                (NP
                  (NP (DT:[954..957] the)
                     (JJ:[959..964] small) (NNS:[965..973] adenomas))
                  (CC:[974..977] and)
                  (NP (DT:[978..981] the)
                     (JJ:[982..990] invasive) (NN:[991..997] cancer)))))))))
    (,:[997..998] ,)
    (VP (VBD:[999..1007] involved)
      (NP
        (NP (NN:[1008..1012] loss))
        (PP (IN:[1013..1015] of)
          (NP
            (NP (NN:[1016..1022] serine)
              (NML-1 (-NONE-:[1022..1022] *P*)))
            (CC:[1023..1025] or)
            (NP (NN:[1026..1035] threonine)
              (NML-1 (NN:[1037..1052] phosphorylation) (NNS:[1053..1058] sites)))))))
    (.:[1058..1059] .)))

;sentence 8 Span:1060..1255
;The percentage of beta-catenin mutations in small  adenomas (12.5%) was
;significantly greater than that in large adenomas (2.4%)  and invasive
;cancers (1.4%; P = 0.05 and P = 0.02, respectively).
;[1078..1090]:gene-rna:"beta-catenin"
;[1104..1119]:malignancy:"small  adenomas"
;[1167..1181]:malignancy:"large adenomas"
;[1194..1210]:malignancy:"invasive cancers"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1060..1063] The) (NN:[1064..1074] percentage))
      (PP (IN:[1075..1077] of)
        (NP (NN:[1078..1090] beta-catenin) (NNS:[1091..1100] mutations)))
      (PP-LOC (IN:[1101..1103] in)
        (NP (JJ:[1104..1109] small) (NNS:[1111..1119] adenomas)))
      (PRN (-LRB-:[1120..1121] -LRB-)
        (NP (CD:[1121..1125] 12.5) (NN:[1125..1126] %))
        (-RRB-:[1126..1127] -RRB-)))
    (VP (VBD:[1128..1131] was)
      (ADJP-PRD
        (ADJP (RB:[1132..1145] significantly) (JJR:[1146..1153] greater))
        (PP (IN:[1154..1158] than)
          (NP
            (NP (DT:[1159..1163] that))
            (PP-LOC (IN:[1164..1166] in)
              (NP
                (NP
                   (JJ:[1167..1172] large) (NNS:[1173..1181] adenomas)
                  (PRN (-LRB-:[1182..1183] -LRB-)
                    (NP (CD:[1183..1186] 2.4) (NN:[1186..1187] %))
                    (-RRB-:[1187..1188] -RRB-)))
                (CC:[1190..1193] and)
                (NP
                   (JJ:[1194..1202] invasive) (NNS:[1203..1210] cancers)
                  (PRN (-LRB-:[1211..1212] -LRB-)
                    (NP (CD:[1212..1215] 1.4) (NN:[1215..1216] %))
                    (::[1216..1217] ;))))))))
      (PRN
        (S
          (S
            (NP-SBJ (NN:[1218..1219] P))
            (VP (SYM:[1220..1221] =)
              (NP (CD:[1222..1226] 0.05))))
          (CC:[1227..1230] and)
          (S
            (NP-SBJ (NN:[1231..1232] P))
            (VP (SYM:[1233..1234] =)
              (NP (CD:[1235..1239] 0.02))))
          (,:[1239..1240] ,)
          (ADVP (RB:[1241..1253] respectively))
          (-RRB-:[1253..1254] -RRB-))))
    (.:[1254..1255] .)))

;sentence 9 Span:1256..1371
;We conclude  that mutation of beta-catenin can be an early, perhaps
;initiating, event in  colorectal tumorigenesis.
;[1286..1298]:gene-rna:"beta-catenin"
(SENT
  (S
    (NP-SBJ (PRP:[1256..1258] We))
    (VP (VBP:[1259..1267] conclude)
      (SBAR (IN:[1269..1273] that)
        (S
          (NP-SBJ
            (NP (NN:[1274..1282] mutation))
            (PP (IN:[1283..1285] of)
              (NP (NN:[1286..1298] beta-catenin))))
          (VP (MD:[1299..1302] can)
            (VP (VB:[1303..1305] be)
              (NP-PRD (DT:[1306..1308] an) (JJ:[1309..1314] early)
                      (,:[1314..1315] ,)
                (ADJP (RB:[1316..1323] perhaps) (VBG:[1324..1334] initiating))
                (,:[1334..1335] ,) (NN:[1336..1341] event))
              (PP (IN:[1342..1344] in)
                (NP (JJ:[1346..1356] colorectal) (NN:[1357..1370] tumorigenesis))))))))
    (.:[1370..1371] .)))

;sentence 10 Span:1372..1616
;Small adenomas with beta-catenin mutations do not  appear to be as likely to
;progress to larger adenomas and invasive carcinomas as  other adenomas,
;however, with the result that beta-catenin mutations are only  rarely seen in
;invasive cancers.
;[1372..1386]:malignancy:"Small adenomas"
;[1392..1404]:gene-rna:"beta-catenin"
;[1461..1476]:malignancy:"larger adenomas"
;[1481..1500]:malignancy:"invasive carcinomas"
;[1511..1519]:malignancy:"adenomas"
;[1551..1563]:gene-rna:"beta-catenin"
;[1599..1615]:malignancy:"invasive cancers"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1372..1377] Small) (NNS:[1378..1386] adenomas))
      (PP (IN:[1387..1391] with)
        (NP (NN:[1392..1404] beta-catenin) (NNS:[1405..1414] mutations))))
    (VP (VBP:[1415..1417] do) (RB:[1418..1421] not)
      (VP (VB:[1423..1429] appear)
        (S
          (NP-SBJ-1 (-NONE-:[1429..1429] *))
          (VP (TO:[1430..1432] to)
            (VP (VB:[1433..1435] be)
              (ADJP-PRD
                (ADJP (RB:[1436..1438] as) (JJ:[1439..1445] likely)
                  (S
                    (NP-SBJ (-NONE-:[1445..1445] *))
                    (VP (TO:[1446..1448] to)
                      (VP (VB:[1449..1457] progress)
                        (PP-CLR (TO:[1458..1460] to)
                          (NP
                            (NP (JJR:[1461..1467] larger)
                                (NNS:[1468..1476] adenomas))
                            (CC:[1477..1480] and)
                            (NP (JJ:[1481..1489] invasive)
                                (NNS:[1490..1500] carcinomas))))))))
                (PP (IN:[1501..1503] as)
                  (NP (JJ:[1505..1510] other) (NNS:[1511..1519] adenomas))))
              (,:[1519..1520] ,)
              (ADVP (RB:[1521..1528] however))
              (,:[1528..1529] ,)
              (PP (IN:[1530..1534] with)
                (NP (DT:[1535..1538] the) (NN:[1539..1545] result)
                  (SBAR (IN:[1546..1550] that)
                    (S
                      (NP-SBJ-2 (NN:[1551..1563] beta-catenin)
                                (NNS:[1564..1573] mutations))
                      (VP (VBP:[1574..1577] are)
                        (ADVP (RB:[1578..1582] only) (RB:[1584..1590] rarely))
                        (VP (VBN:[1591..1595] seen)
                          (NP-2 (-NONE-:[1595..1595] *))
                          (PP-LOC (IN:[1596..1598] in)
                            (NP (JJ:[1599..1607] invasive)
                                (NNS:[1608..1615] cancers))))))))))))))
    (.:[1615..1616] .)))

;sentence 11 Span:1617..1806
;This suggests that APC and beta-catenin  mutations are not functionally
;equivalent, and that the APC gene may have other  tumor suppressor functions
;besides the degradation of beta-catenin.
;[1636..1639]:gene-rna:"APC"
;[1644..1656]:gene-rna:"beta-catenin"
;[1714..1717]:gene-rna:"APC"
;[1793..1805]:gene-protein:"beta-catenin"
(SENT
  (S
    (NP-SBJ (DT:[1617..1621] This))
    (VP (VBZ:[1622..1630] suggests)
      (SBAR
        (SBAR (IN:[1631..1635] that)
          (S
            (NP-SBJ
              (NP (NN:[1636..1639] APC)
                (NML-1 (-NONE-:[1639..1639] *P*)))
              (CC:[1640..1643] and)
              (NP (NN:[1644..1656] beta-catenin)
                (NML-1 (NNS:[1658..1667] mutations))))
            (VP (VBP:[1668..1671] are) (RB:[1672..1675] not)
              (ADJP-PRD (RB:[1676..1688] functionally)
                        (JJ:[1689..1699] equivalent)))))
        (,:[1699..1700] ,) (CC:[1701..1704] and)
        (SBAR (IN:[1705..1709] that)
          (S
            (NP-SBJ (DT:[1710..1713] the) (NN:[1714..1717] APC)
                    (NN:[1718..1722] gene))
            (VP (MD:[1723..1726] may)
              (VP (VB:[1727..1731] have)
                (NP
                  (NP (JJ:[1732..1737] other)
                    (NML (NN:[1739..1744] tumor) (NN:[1745..1755] suppressor))
                    (NNS:[1756..1765] functions))
                  (PP (IN:[1766..1773] besides)
                    (NP
                      (NP (DT:[1774..1777] the) (NN:[1778..1789] degradation))
                      (PP (IN:[1790..1792] of)
                        (NP (NN:[1793..1805] beta-catenin))))))))))))
    (.:[1805..1806] .)))

;section 12 Span:1810..1855
;PMID: 10197610 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1810..1814] PMID) (::[1814..1815] :) (CD:[1816..1824] 10197610)
        (NN:[1825..1826] -LSB-) (NNP:[1826..1832] PubMed) (::[1833..1834] -)
        (NN:[1835..1842] indexed) (IN:[1843..1846] for)
        (NNP:[1847..1855] MEDLINE-RSB-)))
